Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Combined Serum Mesothelin And Carcinoembryonic Antigen Measurement In The Diagnosis Of Malignant Mesothelioma.

K. Fukuoka, K. Kuribayashi, S. Yamada, K. Tamura, C. Tabata, T. Nakano
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Malignant mesothelioma (MM) is a highly aggressive tumor associated with asbestos exposure. The identification of a marker specific for MM may be of considerable value for the early detection of this tumor and may be used in particular to screen groups with a history of asbestos exposure. The aim of this study was to evaluate serum soluble mesothelin-related peptide (SMRP) levels as a diagnostic marker for MM and investigate whether its diagnostic value is enhanced by combination with other biomarkers. Serum SMRP levels were measured using a quantitative enzyme-linked immunosorbent assay in 96 patients with MM, 55 patients with lung cancer and 39 individuals with a history of asbestos exposure. Receiver operating characteristic curves were constructed for performance evaluation. Stepwise logistic regression analysis was used to select marker combinations (MCs). Serum SMRP levels in patients with MM were significantly higher compared to those in the other groups (P<0.001). The sensitivity of SMRP levels in diagnosing MM was 56% and its specificity for MM vs. lung cancer and individuals with asbestos exposure was 87 and 92%, respectively. The area under the curve (AUC) was 0.76 [95% confidence interval (CI): 0.68-0.83] for the differentiation between MM and lung cancer and 0.78 (95% CI: 0.71-0.86) for the differentiation between MM and individuals with asbestos exposure. For the MC of presence of effusion, SMRP and carcinoembryonic antigen (CEA) levels, the AUC for the differentiation between MM and lung cancer (0.92; 95% CI: 0.88-0.97) and the differentiation between MM and individuals with asbestos exposure (0.93; 95% CI: 0.87-1.0) was significantly higher compared to that for SMRP alone (P=0.0001 and 0.0058, respectively). While the specificity of this MC was comparable to SMRP alone, its sensitivity was ∼20% higher compared to that of SMRP alone. Therefore, combining SMRP and CEA improves the diagnostic performance of SMRP alone. A combination of serum biomarkers, including SMRP, may facilitate the non-invasive diagnosis of MM.
This paper references
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1097/JTO.0b013e318187491c
Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer
J. Schneider (2008)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1158/1078-0432.CCR-03-0801
Mesothelin: a new target for immunotherapy.
R. Hassan (2004)
10.1158/1055-9965.EPI-07-0607
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
M. Amati (2008)
10.1097/JTO.0b013e31821e1c08
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
A. Cristaudo (2011)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.2307/2531595
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
E. R. Delong (1988)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
Cyfra 21-1 and TPA as markers in malignant mesothelioma.
J. Bonfrer (1997)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1515/CCLM.2010.066
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels
A. Rai (2010)
10.1158/1078-0432.CCR-03-0365
Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer
J. Schorge (2004)
10.1016/J.LUNGCAN.2007.08.030
Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
M. Van den Heuvel (2008)
10.1016/S0169-5002(99)00044-6
Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
H. Schouwink (1999)
10.1038/bjc.2011.104
Markers for the non-invasive diagnosis of mesothelioma: a systematic review
S. van der Bij (2011)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.3233/CBM-2007-3602
Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.
D. Weber (2007)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1378/CHEST.119.4.1138
Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
M. Paganuzzi (2001)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
Osteopontin as an Adjunct to CA 125 in Detecting Recurrent Ovarian Cancer
J. Schorge (2004)
10.1016/j.lungcan.2011.02.007
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
J. Creaney (2011)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1016/S0169-5002(03)92469-X
Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma.
M. Hedman (2003)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1097/01.JTO.0000283758.23717.5C
P1-144: Soluble Mesothelin related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison to Asbestos Diseases and Lung Cancer
T. Muley (2007)
Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
Ruth Etzioni (2004)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.2217/bmm.11.18
Soluble markers for diagnosis of malignant pleural mesothelioma.
A. Cristaudo (2011)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1097/00000478-200311000-00003
Application of Mesothelin Immunostaining in Tumor Diagnosis
N. Ordóñez (2003)



This paper is referenced by
10.1136/oemed-2016-104024
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals
C. De Santi (2017)
10.7314/APJCP.2016.17.3.1163
Plasma Peptidome as a Source of Biomarkers for Diagnosis of Cholangiocarcinoma.
Kanawut Kotawong (2016)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
Advances in the Medical Treatment of Malignant
K. Fukuoka (2014)
10.21037/jtd-20-1910
Three tumor markers for improved efficacy in the management of patients with malignant pleural mesothelioma.
Akifumi Nakamura (2020)
10.1155/2014/161954
Preoperative Serum Levels of Mesothelin in Patients with Colon Cancer
O. Bostanci (2014)
Pericardial mesothelioma with severe congestive heart failure in a Holstein cow
Haruka Suzuki (2017)
10.1007/s00408-019-00244-1
Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma
Carmina Jiménez-Ramírez (2019)
10.1155/2017/3510984
A Novel Panel of Serum Biomarkers for MPM Diagnosis
A. Bonotti (2017)
10.4081/rt.2015.5947
Peritoneal Malignant Mesothelioma with Epithelioid Type, Demonstrating High Serum and Ascitic KL-6 Levels: Immunohistochemical Analyses
S. Nahar (2015)
Investigating methods regarding diagnostic and prognostic biomarkers for malignant mesothelioma
H. Matsuzaki (2015)
Eradication of established murine mesothelioma tumours by combined immunotherapy
Shruti Krishnan (2015)
10.1016/j.freeradbiomed.2015.05.002
Malignant mesothelioma as an oxidative stress-induced cancer: An update.
S. H. Chew (2015)
Advances in the Medical Treatment of Malignant Mesothelioma
K. Kuribayashi (2014)
10.1016/j.lungcan.2015.09.021
Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
L. Santarelli (2015)
Semantic Scholar Logo Some data provided by SemanticScholar